Intrinsic value of Concert Pharmaceuticals, Inc. (CNCE)

Previous Close$6.37
Intrinsic Value
Upside potential
Previous Close

VALUATION INPUT DATA (original, your and others' valuations)

Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh4.15 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.

show cash flow forecast


Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046


Revenue growth rate, %312.3NaN
Revenue, $33NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m110NaN
Operating income, $m-78NaN
EBITDA, $m-76NaN
Interest expense (income), $mNaN
Earnings before tax, $m-80NaN
Tax expense, $m0NaN
Net income, $m-80NaN


Cash and short-term investments, $m143NaN
Total assets, $m165NaN
Adjusted assets (=assets-cash), $m22NaN
Average production assets, $m13535NaN
Working capital, $m134NaN
Total debt, $m15NaN
Total liabilities, $m53NaN
Total equity, $m112NaN
Debt-to-equity ratio0.134NaN
Adjusted equity ratio-1.338NaN


Net income, $m-80NaN
Depreciation, amort., depletion, $m2NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-54NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-0NaN
Free cash flow, $m-54NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m134
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN